OMNI BIO PHARMACEUTICAL, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+66.67% | +233.33% |
| 2016 | Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015 | CI |
| 2015 | Omni Bio Pharmaceutical, Inc. Announces Management Changes | CI |
Financials (USD)
| Sales 2013 | - | Sales 2014 | - | Capitalization | 10.89M |
|---|---|---|---|---|---|
| Net income 2013 | -7M | Net income 2014 | -2M | EV / Sales 2013 | - |
| Net Debt 2013 | 441K | Net Debt 2014 | 752K | EV / Sales 2014 | - |
| P/E ratio 2013 |
-1.5
x | P/E ratio 2014 |
-4.18
x | Employees | - |
| Yield 2013 * |
-
| Yield 2014 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Omni Bio Pharmaceutical, Inc. is a United States-based company that operates as a biopharmaceutical company. The Company is focused on the treatment of immune-mediated inflammatory disease. The Company is providing recombinant version of plasma-derived alpha-1 antitrypsin (p-AAT) platform for intravenous supplementation therapy.
| 1st Jan change | Capi. | |
|---|---|---|
| +233.33% | 50.06K | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- OMBP Stock
